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ABSTRACT 
In present study, BLAST search was performed and an identity with Trypanosoma brueei is 79% Based upon and Pfam results Enolase- 2PTZ 
(protein data bank) was considered as an ideal homologue and used as a template for homology modeling due to its higher X-ray resolution at 
1.65. Sequence alignment between enolase and 2PTZ was done using align 123 followed by manual modification. The final alignment was 
carefully evaluated and evidenced to be matching the conserved residue data for chain A of enolase in Trypanosoma brucei well Superimposing of 
the model was done over the template 2PTZ. Further research on the comparison of the models for the inhibitors may eluciadate the mechanism 
of enolase ligands interactions. This study has shown that some formation of favorable hydrogen bonds, hence it is predicated from this study 
that these novel compounds may act as potent inhibitors for Leishmania Enolase. These compounds may be used further for synthesis, their wet 
lab activity against Enolase, animal model study and clinical trials and then can be implicated for the treatment of leishmaniasis. Those models 
are considered to be used in designing new leads for hopefully more active compounds. 
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INTRODUCTION 
Leishmaniasis is a disease caused by protozoan parasites 
that belong to the genus Leishmania and is transmitted by 
the bite of certain species of sand fly (subfamily 
phlebotomine) 1-2. Two genera tranprit Leishmania to 
humans “Lutzomyia in the New World and Phlebotomus in 
the Old World” (1). The disease was named in 1901 after the 
Scottish pathologist William Boog Leishman. This disease is 
also known as Leichmaniosis, Leishmaniose, Leshmaniose, 
and formerly, Orient Boils, Aleppo Boil, Baghdad Boil, Kala 
azar, Black fever, sand fly disease, Dum-Dum fever, chiclero 
uleer or espundia3-6.  
Most forms of the disease are transmissible only from 
animals (zoonosis). But some can be spread between 
humans. Human infection is caused by about 21 of 30 species 
that infect mammals. These include the L. donovani complex 
with three species (L. donovani, L. infantum and L. chagasi); 
These include the L. Mexicana complex with 3 main species 
(L. Mexicana, L. amazonensis and L. venezuelensis); L. tropica: 
L. major: L. aethiopica; and the subgenus Viamia with four 
main species (L.(V.) braziliensis, L. (V) guyanensis, L. (V.) 
panamensis, and L. (V.) peruviana). The different species are 
morphologically indistinguishable, but they can be 
differentiated by isoenzyme analysis, DNA sequence analysis, 
or monoclonal antibodies7-11.  
Current drug treatment for Leishmania is either lacking or 
unsatisfactory and new drugs for clinical use are too 
expensive to develop through classical empirical screening 
methods. Antimonials (pentavalent) has 28-day 
intramuscular- or intravenous-injection regimen. Resistance 
reported in as many as 60 percent of cases in parts of India. 
Expensive (if name brand product) 12-15. Otherwise the 
generic SSG is relatively cheap (US$ 30). Infusion side effects 
include nausea, pain, anorexia, myalgia arthralgia, headache, 
malaise, reversible cardiotoxicity and chemical and clinical 
pancreatitis. Amphotericin B has 4-8 week intravenous 
regimen but is expensive, side effects include fever, chills, 
hypokalaemia, renal toxicity, anaemia and cardiotoxicity, 
AmBisome has 5-day intravenous regimen, Liposomal 
Amphotericin B (encapsulated in liposomes) is well 
tolerated, but is expensive, Miltefosine has 28 day oral 
regimen but is expensive, risk of teratogenicity16-17. 
MATERIALS AND METHODS 
Protein Structure Predication  
Knowledge of the three-dimensional structure is a 
prerequisite for rational drug design. X-ray crystallography, 
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NMR spectroscopy and electron microscopy are most 
important experimental methods to obtain detailed 
structure information.  
Protein and nucleic acid sequence methods are now well 
advanced and available in many laboratories. As a result 
sequence database such as Swiss-prot. TreMBL 
(http://www.expasy.ch/), and the protein information 
resource (PIR), (http://www- nbrf.georgetown.edu/), have 
been growing rapidly in recent years. In contrast the 
determination of protein structure by NMR or X-ray 
crystallography has tended to proceed much more slowly. 
Hence there are many important proteins where the 
sequence is available but the three-dimensional structure is 
not yet known. The gap between the number of known 
sequences and the number of known structure is widening 
rapidly and the most successful theoretical approach to 
bridging this gap is homology modeling.  
The objective of homology modeling is to build a 3D model 
for a protein of which the structure is unknown (the target) 
on the basis of sequence similarity to proteins of known 
structure (the templates). The technique uses experimentally 
determined protein structure to predict the conformation of 
another protein that has a similar amino acid sequence. The 
method relies on the observation that in nature the structure 
conformation of a protein is more highly conserved than its 
amino acid sequence and that small or medium changes in 
sequence typically result in only small changes in the 3D 
structure. Homology modeling or comparative modeling 
methods are able to predict the 3D structure of a protein 
sequence by using information derived from a homologous 
protein of known structure. 
RESULTS AND DISCUSSION 
Sequence Retrieval Form SWISSPROT: 
Protein sequence database which strives to provide a high 
level of annotation (such as the description of the function of 
a protein, its domains structure, post- translational 
modifications, variants, etc.), a minimal level of redundancy 
and high level of integration with other database. 
Amino Acid Sequence of Target 
>gi|190335775|gb|ACE74540.1|enolase[Leishmania 
donovani] 
MPIRKVYAREVLDSRGNPTVEVELMTEAGVFRSAVPSGASTGV
HEACELRDGDKARYCGAGCTQAVKNVEILAPALVGKDESDQAG
LDKMMCELDGTKNKSKLGANAILGCSMAISKAAAAKAGVPLYR
YIAGLAGTKDIRLPVPCFNVINGGKHAGNVLPFQEFMIAPTKAT
SFREALRMGSEVYHALKVHKSKYGQDAVNVGDEGGFAPPIKHI
DEPLPHMEAIEKAGHKGKFAICMDCAASEAYDAERKMYNLTFK
NPEPTYVSAAELQATYERWVAEYPLVSIEDPFAEDNFDEFSATT
MALAGKAQIVGDDLTVTNVERVKMAIEKSACNSLLLKINQIGTIS
ESIAAAKLCMENGWSVMVSHRSGETEDTYIADLSVGLGTGOIKT
GAPCRGERTAKLNQLLRIEEEIGSTATYGYPGWA 
Amino Acid Sequence of Template  
>gi|160877729|pdb|2PTZ|A Chain A, Crystal Structure of the 
T, Brucci Enolase Complexed with 
Phosphonoacetohydroxamate (path), His 156-Out 
Conformation 
GSHMTIQKVHGREVLDSRGNPTVEVEVTTEKGVFRSAVPSGAS
TGVYEACELRDGDKKRYVGKGCLQAVKNVEVIGPALIGRDELKQ
EELDTLMLRLDGTPNKGKLGANAILGCSMAISKAAAAAKGVPLY
RYLASLAGTKELRLPVPCFNVINGGKHAGNALPFQEFMIAPVKA
TSFSEALRMGSEVYHSLRGIIKKKYGQDAVNVGDEGGFAPPIKDI
NEPLPILMEAIEEAGHRGKFAICMDCAASETYDEKKQQYNLTFK
SPEPTWVTAEQLRETYCKWAHDYPIVSIEDDPYDQDDFAGFAG
ITEALKGKTQIVGDDLTVTNTERIKMAIEKKACNSLLLKINQIGTI
SEAIASSKLCMENGWSVMVSHRSGETEDTYIADLVVALGSGQIK
TGAPCRGERTAKLNQLLRIEEELGAHAKFGFPGWS 
BLAST (Basic Local Alignment Search Tool) 
BLAST search was performed against protein data bank 
(PDB) with the default parameter to find suitable template 
for homology modelling. Sequence was aligned and the one 
that showed the maximum identity with high score and 
lower e- value and 79% sequence identity were used as a 
reference structure to build a 3D model for Enolase 
respectively. The Enolase was modelled by means of 
comparative modelling procedure using the PDB having ID 
“2ptz” as template for Enolase. 
Query ID   gi|190335775|gb|ACE74540.1| 
Description enolase  Leishmania donovani 
Molecule type  amino acid 
Query Length   429 
Database Name   pdb 
Description  PDB protein database  
Program   BLASTP  
Sequence alignment provides a powerful way to compare 
novel sequence with previously characterized genes. Both 
function and evolutionary information can be inferred form 
well designed queries and alignments. BLAST 2.0, (Basic 
Local Alignment Search Tool), provides a method for rapid 
searching of nucleotide and protein databases. Since the 
BLAST algorithm detects local as well as global alignments, 
regions of similarity embedded in otherwise unrelated 
proteins can detected. Both types of similarity may provide 
may provide important clues to the function of 
uncharacterized proteins. 
Choice of Template 
Comparative modeling usually starts with searching the PDB 
of known protein structure using target sequence as the 
Query. This search is generally done by comparing the target 
sequence with the sequence of each of the structure in the 
database. The most popular programs in the class include 
FASTA and BLAST. 
Once a list of potential templates is obtained using searching 
methods, it is necessary to select one or more templates that 
appropriate for the particular modeling problem. The quality 
of a template increases with its overall sequence similarity to 
the target and decreases with the number and length of gaps 
in the alignment. The simplest template section rule is to 
select the structure with the highest sequence similarity to 
the modeled sequence. 
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BLAST Result of Enolase 
PDB ID Name of template Identity 
2ptz Crystal structure of the T. Brucei Enolase complexed with phosphonoacetohydroxamate (pah) 79% 
 
Sequence Allgnment by CLUSTAL W 
Alignment of sequence with their templates structure was 
done using the Clustal W. The software also takes into 
account structural information from the template when 
constructing an alignment. The MODELLER script was used 
for alignment all target sequence s in the Ail file with their 
corresponding template structure in the PDB files. Finally, 
the alignment was written out in two formats, PIR and PAP. 
The PIR format is used by MODELLER I the subsequence 
model building stage, while the PAP alignment format is 
easier to inspect visually. In the PAP format, all identical 
positions are marked with a ‘*’. The details of modelling and 
sequence alignment scripts are submitted as supplementary 
material. 
CLUSTAL W (1.83) multiple sequence alignment 
CONCLUSION 
Leishmania enolase is potential target for treating visceral 
Leishmaniasis. In order to understand structural features we 
carried out homology modelling of Leishmania donovani 
enolase. Developed model shows good overall structural 
quality as validated by using different validation tools like 
Procheck, verify 3d SCORE. In addition, model shows good 
native protein folding. The ligand active site was determined 
by sequence alignment and Q site finder analysis tool. The 
amino acid residues lys155, eys 147 and cys241 of enolase of 
Leishmania donivani are active site residues, which were 
exploited to design target specific inhibitors. The enolase 
model was taken for further screening of different chemical 
library to studying their enolase inhibitory activities; 
different public domain chemical libraries were accessed for 
this study. 
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